INTRODUCTION
============

The term "cancer chemoprevention" was introduced by Michael B. Sporn, at the US National Institutes of Health (NIH) in Bethesda, Maryland ([@b43-molce-41-2-73]), and Japanese cancer researchers became interested in screening for possible cancer preventive agents in the 1980s. We assumed that inhibitors of tumor promotion would be cancer preventive compounds, since they had been known to suppress experimentally induced tumor development in rodents ([@b5-molce-41-2-73]). Since green tea is a daily beverage in Japan, we paid special attention to green tea catechins, especially its main constituent (−)-epigallocatechin gallate (EGCG), for our main experiments ([@b11-molce-41-2-73]). In 1987, we reported for the first time that topical applications of EGCG significantly prevented tumor promotion in mouse skin induced by teleocidin, one of the 12-*O*-tetradecanoylphorbol-13-acetate (TPA)-type tumor promoters ([@b62-molce-41-2-73]). Soon after publication, the British journal "New Scientist" introduced our research on cancer prevention with EGCG under the title of "Green tea cuts cancerous growths" ([@b9-molce-41-2-73]). In quick response to this article, staff members of the Australian TV scientific series "Beyond 2000" visited us in Tokyo: They made a film about our experiments in cancer prevention with green tea catechins, and the film was released in Australia, U.S.A., England and Europe in 1988. It was followed by "Beyond Tomorrow" on American TV in 1988. Many overseas scientists then became greatly interested in cancer prevention with green tea, some of them even more interested than Japanese scientists.

Since then, numerous scientists have shown that EGCG and green tea extract in drinking water prevent carcinogenesis in various organs of rodents ([@b6-molce-41-2-73]; [@b21-molce-41-2-73]; [@b13-molce-41-2-73]; [@b23-molce-41-2-73]; [@b52-molce-41-2-73]; [@b60-molce-41-2-73]; [@b61-molce-41-2-73]; [@b63-molce-41-2-73]). The results are supported by our experiments showing that intubation of ^3^H-EGCG into mouse stomach distributed radioactivity in a wide range of target organs, and subsequent treatment of cells with ^3^H-EGCG showed radioactivity inside the cells ([@b36-molce-41-2-73]; [@b47-molce-41-2-73]). Based on results showing that the inhibitory effects of EGCG and green tea extract on the growth of human lung cancer cell lines PC-9 and PC-14 were approximately 250-fold less effective than adriamycin ([@b29-molce-41-2-73]), we conceived the development of EGCG and green tea extract as cancer preventives, rather than cancer therapeutic drugs.

We have studied cancer prevention with green tea for over 30 years, and our collaborations have produced numerous significant results, both from basic studies and with cancer patients and the general human population ([@b15-molce-41-2-73]; [@b16-molce-41-2-73]). This review consists of two parts, and the first part summarizes epochal results by way of introduction: 1) A prospective cohort study revealed that drinking 10 Japanese-size cups (120 ml/cup) of green tea per day delayed cancer onset 7.3 years for female patients ([@b25-molce-41-2-73]; [@b34-molce-41-2-73]); 2) A randomized phase II clinical prevention trial showed that drinking 10 Japanese-size cups of green tea, supplemented with green tea tablets, significantly reduced tumor recurrence in patients with colorectal adenomas ([@b40-molce-41-2-73]); 3) Peroral administration of EGCG in drinking water prevented both hematogenous and lymphogenous (spontaneous) lung metastases of B16 melanoma cells in male C57BL/6 mice ([@b55-molce-41-2-73]); 4) Treatment of B16-F10 mouse melanoma cells with EGCG increased the average value of Young's moduli as assessed by the atomic force microscope (AFM), i.e., cell stiffness, and inhibited cell motility ([@b59-molce-41-2-73]); and 5) The combination of EGCG and anticancer compounds induced apoptosis and increased efficacy of anticancer activity in rodents, and also showed synergistic enhancement of anti-cancer activity against human cancer cell lines ([@b48-molce-41-2-73]; [@b49-molce-41-2-73]; [@b50-molce-41-2-73]). Green tea is a cancer preventive for primary cancer prevention, and green tea catechins act as synergist with anticancer drugs in tertiary cancer prevention ([Fig. 1](#f1-molce-41-2-73){ref-type="fig"}) ([@b10-molce-41-2-73]; [@b16-molce-41-2-73]; [@b18-molce-41-2-73]; [@b19-molce-41-2-73]).

The second part of this review shows the molecular mechanisms of anticancer activity of EGCG against human cancer stem cells (CSCs). We first found that repeated applications of 5 mg EGCG before each treatment with 1 μg okadaic acid - a potent tumor promoter and inhibitor of protein phosphatases 1 and 2A - completely prevented tumor promotion in mouse skin, in two-stage carcinogenesis experiments initiated with 7,12-dimethylbenz(a)anthracene (DMBA), and that treatment with DMBA plus okadaic acid produced tumors in 73.3% of mice at week 20 ([@b12-molce-41-2-73]; [@b46-molce-41-2-73]). We believe that EGCG treatment inhibited the interaction of tumor promoters, such as okadaic acid, TPA and teleocidin with their receptors, and theorized that EGCG can interrupt the interaction of ligand with its receptor on cell membrane. This is now called the "Sealing effects of EGCG" ([Fig. 2](#f2-molce-41-2-73){ref-type="fig"}) ([@b63-molce-41-2-73]): We thus decided to study cancer stem cells in mouse skin as a target of cancer prevention. In 2012, Srivastava's group reported that EGCG inhibited viability of human pancreatic CSCs in primary and secondary spheroids, as well as expression of pluripotency-maintaining factors in the CSCs ([@b54-molce-41-2-73]). Recently we published a review article on the anticancer activity of EGCG against various human CSCs enriched from cancer cell lines ([@b20-molce-41-2-73]). We then discuss: 1) Cancer stem cells in mouse skin carcinogenesis, 2) Expression of stemness markers of human CSCs enriched from colorectal and nasopharyngeal cancer cell lines, compared with their parental cells, and 3) Decrease or increase in the expression of mRNA and protein in human CSCs of breast, lung and colorectal cancers after treatment with EGCG. The inhibitory effects of EGCG on self-renewal and expression of transcription factors in human CSCs derived from various cancer tissues are emphasized. It has now become clear that human CSCs are effective targets for prevention and treatment using EGCG and green tea extract.

DELAYED CANCER ONSET REVEALED BY 10-YEAR PROSPECTIVE COHORT STUDY
=================================================================

Nakachi and Imai found a total of 419 cancer patients, 175 females and 244 males, during 10 years, from a survey living habits of 8,552 individuals aged over 40 living in Saitama Prefecture, including their daily consumption of green tea ([@b25-molce-41-2-73]; [@b34-molce-41-2-73]). They reported that cancer onset in female patients who had consumed over 10 Japanese-size cups (120 ml/cup) of green tea per day was 7.3 years later than that of patients who had consumed less than three cups per day ([Table 1](#t1-molce-41-2-73){ref-type="table"}). The difference between females and males may be partly due to higher tobacco consumption by males. Consuming over 10 cups of green tea per day (corresponding to 2.5 g green tea extract) also significantly prevented lung cancer, with a relative risk of 0.33, followed by cancers of the colorectum, liver and stomach, in that order ([@b25-molce-41-2-73]; [@b34-molce-41-2-73]). Results of two research groups: Green tea catechins at 600 mg per day were effective for treating premalignant lesions before prostate cancer development, research conducted at University of Parma, Italy ([@b3-molce-41-2-73]): and green tea extract showed preventive effects on oral premalignant leukoplakia in patients, at the University of Texas M.D. Anderson Cancer Center ([@b58-molce-41-2-73]).

Nakachi and Imai also studied recurrence of breast cancer among the 472 cancer patients: Stages I and II cancer patients consuming over five cups of green tea per day (average 8 cups) showed a lower recurrence rate, 16.7%, and a longer disease-free period, 3.6 years, than those consuming less than four cups per day (average 2 cups), 24.3% and 2.8 years ([Table 2](#t2-molce-41-2-73){ref-type="table"}) ([@b33-molce-41-2-73]). However, in Stage III breast cancer patients, green tea did not show any decreased recurrence because Stage III breast cancer includes more accumulated genetic changes in the cells than are found in Stages I and II. The results were later confirmed at Aichi Cancer Center ([@b26-molce-41-2-73]), and at Harvard T.H. Chan School of Public Health in the United States ([@b35-molce-41-2-73]).

Since humans are always at risk of tumor promotion induced by inflammation, we need to establish a cancer prevention strategy that can reduce TNF-α, IL-1 and other proinflammatory cytokines, and inactivate NF-κB ([@b17-molce-41-2-73]). The key point is: Drinking green tea contributes to primary cancer prevention ([Fig. 1](#f1-molce-41-2-73){ref-type="fig"}).

PREVENTION OF COLORECTAL ADENOMA RECURRENCE WITH 10 JAPANESE-SIZE CUPS OF GREEN TEA PER DAY SUPPLEMENTED WITH GREEN TEA TABLETS
===============================================================================================================================

The Saitama Prefectural Tea Research Institute began to produce tablets of green tea extract (G.T.E), which is the dried form of green tea beverage. One tablet is equivalent to approximately 2 Japanese-size cups of green tea. One hundred two healthy citizens of Saitama Prefecture joined the preclinical safety trial of G.T.E, with informed consent. The blood examination did not show any serious effects, and 93% of the participants were able to continue drinking green tea beverage and also taking G.T.E ([@b14-molce-41-2-73]). Because some of the subjects had very mild temporary disorders, the Tea Research Institute subsequently reduced the caffeine content of the tablets from 5% to less than 3% without using an organic solution.

Moriwaki's group at Gifu University conducted a double-blind randomized clinical phase II prevention trial of colorectal adenoma recurrence with subjects drinking 10 cups of green tea supplemented with tablets of G.T.E, with informed consent. Patients without colon adenomas were then double-blind randomized into two groups: Control group maintained daily consumption of green tea beverage only, without a placebo, and G.T.E group took the daily beverage plus 3 tablets (equivalent to 6 cups) per day, corresponding to over 10 cups, about 2.5 g green tea extract, for 12 months. The incidence of recurrent adenomas was determined by end-point colonoscopy 12 months later: Control group showed 31.0% recurrence rate, while the G.T.E group rate was 15.0%, and the average size of relapsed adenomas was 3.0 ± 1.0 mm in the G.T.E. group and 4.0 ± 1.3 mm in control group (*P* \< 0.001) ([Table 3](#t3-molce-41-2-73){ref-type="table"}). Thus, drinking 10 Japanese-size cups of green tea, supplemented with G.T.E, significantly, 51.6%, reduced recurrence of colorectal adenomas ([@b40-molce-41-2-73]).

Similar results were confirmed at different institutions: drinking green tea extract prevented 44.2% of colorectal adenoma recurrence in Korean patients at Seoul National University ([Table 3](#t3-molce-41-2-73){ref-type="table"}) ([@b41-molce-41-2-73]), and the flavonoid mixture (daily standard dose, 20 mg apigenin and 20 mg EGCG) reduced the recurrence rate of colon neoplasia in patients with resected colon cancer at the Hospital of Gross-Gerau, Germany ([@b24-molce-41-2-73]). And a plan for the first large-scale placebo-controlled prevention trial for metachronous adenoma recurrence in the colorectum of patients, using green tea extract for three years, is conducted at University Ulm, Germany ([@b45-molce-41-2-73]). All the results show that drinking green tea is effective for tertiary cancer prevention ([Fig. 1](#f1-molce-41-2-73){ref-type="fig"}).

INHIBITION OF METASTASES OF B16 MELANOMA CELLS TO THE LUNGS OF MICE BY DRINKING EGCG
====================================================================================

Taniguchi's group reported for the first time that oral administration of EGCG inhibited lung metastases of two different B16 melanoma variants in two experimental models ([@b55-molce-41-2-73]). Hematogenous metastasis was induced with intravenous injection of highly metastatic B16-F10 cells in male C57BL/6 mice given a solution of 0.05% and 0.1% EGCG. Lymphogenous (spontaneous) metastasis was induced by inoculation of highly metastatic and invasive B16-BL6 cells into the right foot pads of male C57BL/6 mice, given the same solutions of EGCG. EGCG reduced the average number of lung nodules ([Table 4](#t4-molce-41-2-73){ref-type="table"}) ([@b55-molce-41-2-73]). To understand the inhibitory effects of EGCG on metastasis, Suganuma's group further studied the biophysical effects of EGCG on cell stiffness and motility ([@b51-molce-41-2-73]).

GREEN TEA AND EGCG INCREASED THE AVERAGE VALUE OF YOUNG'S MODULUS OF CANCER CELLS (CELL STIFFNESS) AND INHIBITED CELL MOTILITY
==============================================================================================================================

Cell stiffness can be determined using atomic force microscope (AFM), which quantitatively provides the average value of Young's modulus of cancer cells. In 2007, Gimzewski's group at UCLA reported that metastatic cells in pleural fluids obtained from lung, breast, and pancreatic cancer patients have significantly lower average values of Young's modulus with less stiffness (equivalent to smaller elasticity) - determined using AFM - than normal mesothelial cells in the body fluids ([@b7-molce-41-2-73]). They also found that green tea extract dramatically increased cell stiffness of metastatic cancer cells, from 0.43 kPa to 2.53 kPa, about 6.2-fold, based on the average value of Young's moduli in nine cancer cell lines ([@b8-molce-41-2-73]). The results indicated that AFM can measure the changes in cell stiffness induced by EGCG.

To study the relationship between increased average value of Young's moduli and reduction of cell motility by Transwell assay, we used three metastatic B16 mouse melanoma variants for experiments: B16-F10 cells are most motile, B16-BL6 cells, medium motile and B16-F1 cells, least motile. Young's modulus of the most motile B16-F10 cells showed significantly lower cell stiffness, i.e., more soft elasticity, than those of B16-BL6 cells and B16-F1 cells. Furthermore, treatment of B16-F10 cells with 100 μM EGCG increased the average value of Young's modulus to 0.68 ± 0.03 from 0.44 ± 0.01 kPa of non-treated B16-F10 cells ([Table 5](#t5-molce-41-2-73){ref-type="table"}). The results indicated that EGCG increased the average value of Young's modulus for B16-F10 cells (0.68 kPa), which was comparable to that of the least motile B16-F1 cells (0.72 kPa) without EGCG, showing that treatment with EGCG increased stiffness. Moreover, treatment of B16-F10 cells with EGCG (50 -- 200 μM) dose-dependently reduced the motility of the cells to 57.1, 30.3 and 12.6%, respectively ([Table 5](#t5-molce-41-2-73){ref-type="table"}), without affecting viability of the cells ([@b59-molce-41-2-73]). Thus, EGCG simultaneously increased cell stiffness and enhanced inhibition of cell motility ([Fig. 2](#f2-molce-41-2-73){ref-type="fig"}).

Suganuma's group found that treatment of human non-small cell lung cancer cell lines H1299 and Lu99 with EGCG (5 -- 50 μM) for 4 h significantly increased the average value of Young's moduli from 1.24 ± 0.05 to 2.25 ± 0.11 kPa in H1299 cells, and from 1.29 ± 0.11 to 2.28 ± 0.09 kPa in Lu99 cells, showing a 2-fold increase of cell stiffness ([Table 6](#t6-molce-41-2-73){ref-type="table"}) ([@b51-molce-41-2-73]; [@b53-molce-41-2-73]). The results showed that EGCG reduces membrane fluidity - increases rigidification of cell membrane - the cell stiffness of H1299 and Lu99, indicating that EGCG can reduce highly metastatic potential of both cell lines ([Fig. 2](#f2-molce-41-2-73){ref-type="fig"}).

SYNERGISTIC ENHANCEMENT OF ANTICANCER ACTIVITY AGAINST HUMAN CANCER CELL LINES WITH THE COMBINATION OF EGCG AND ANTICANCER COMPOUNDS
====================================================================================================================================

In 2011, Suganuma's group published a review article entitled "New cancer treatment strategy using combination of green tea catechins and anticancer drugs" in Cancer Sci. ([@b50-molce-41-2-73]). The Publisher, Wiley-Blackwell at the Annual Meeting of Japanese Cancer Association, announced that our review article was No. 1 among most read articles and No. 2 among most cited articles in 2012. Since then, numerous scientists around the world have become greatly interested in the combination. We briefly showed that the combinations of EGCG or other green tea catechins and 46 anticancer drugs all synergistically induced *in vitro* anticancer effects in 58 human cancer cell lines ([@b18-molce-41-2-73]; [@b19-molce-41-2-73]).

It is important to note that the enhanced anticancer activity of the combination was demonstrated by reduction of tumor volume in xenograft mouse models in 13 *in vivo* experiments: human cancer cell lines from head and neck, lung, breast, prostate, liver, and stomach were implanted in experiments conducted by numerous investigators ([@b18-molce-41-2-73]; [@b19-molce-41-2-73]). It is striking that the combinations of EGCG and paclitaxel, and EGCG and docetaxel, completely eliminated tumors of human prostate cancer cell line PC-3ML *in vivo* ([Table 7](#t7-molce-41-2-73){ref-type="table"}) ([@b44-molce-41-2-73]). In addition, average reduction of tumor volume (% of control) for the groups treated with vehicle (control), EGCG alone, anti-cancer drugs alone, and combinations were 100%, 73.5%, 66.3%, and 29.7%, respectively ([Table 7](#t7-molce-41-2-73){ref-type="table"}). Thus, the combinations of EGCG and anticancer drugs significantly and synergistically reduced tumor volume by 70.3%, while treatment with EGCG or green tea extract alone was slightly less effective than that with anticancer drugs alone. When the amount of EGCG necessary for the complete elimination of tumors in mice is converted to that for humans, it would be 6 -- 9 Japanese-size-cups of green tea, i.e., 1.37 -- 2.05 g EGCG/day/person ([@b10-molce-41-2-73]; [@b18-molce-41-2-73]; [@b19-molce-41-2-73]).

CANCER STEM CELLS IN MOUSE SKIN CARCINOGENESIS
==============================================

Two-stage chemical carcinogenesis in mouse skin, initiation and tumor promotion, is a useful model for studying tumor promotion and cancer chemoprevention ([@b5-molce-41-2-73]). We found that repeated applications of 5 mg EGCG before each treatment with 1 μg okadaic acid completely prevented tumor promotion in mouse skin initiated with DMBA ([@b63-molce-41-2-73]). At that time, the dark basal keratinocytes in normal epidermal cells were assumed to be stem cells in two-stage carcinogenesis experiments in mouse skin ([@b42-molce-41-2-73]). The epidermis is believed to contain two types of proliferating cells: stem cells and cells with a lower capacity for self-renewal and higher probability of undergoing terminal differentiation (transit amplifying cells) ([@b27-molce-41-2-73]). The removal of the interfollicular epidermis from carcinogen-exposed mice, using an abrasion technique, reduced by half the number of papillomas, while the number of carcinomas remained the same in both abraded and unabraded mice ([@b32-molce-41-2-73]). Stem cells are generally characterized by slow cycling, unlimited self-renewal, and multipotentiality, and they can commit to a variety of cell lineages that comprise the tissue of origin. Initiated label-retaining cells are clonogenic and differentiation-resistant, and hence a likely target for the mutagenic activity of chemical initiators and ultraviolet light ([@b22-molce-41-2-73]). Mouse keratinocyte stem cells with CD34^+^ and cytokeratin 15^+^ (K15) are located only in the outer root sheath of a specific niche within the hair follicle defined as "the bulge," which is thought to contain stem cells ([@b1-molce-41-2-73]). Trempus's group reported that the back skin of CD34 knockout mice (CD34KO) initiated with DMBA and promoted with TPA failed to develop papillomas by week 20, compared with the wild-type mice. This suggests that CD34 is required for TPA-induced hair follicle stem cell activation and tumor formation in mice ([@b57-molce-41-2-73]). Blanpain's group showed that cancer stem cells (CSCs) of skin papillomas are localized in a perivascular niche, and that vascular endothelial growth factor (VEGF) affects skin tumor growth by promoting cancer stemness (the ability to self-renew and differentiate) and symmetric CSC division, leading to CSC expansion ([@b2-molce-41-2-73]). Furthermore, they reported that SRY (sex determining region Y)-box 2 (Sox2) is the most upregulated transcription factor in the CSCs of squamous skin tumors in mice, and that Sox2 is absent in normal epidermis but begins to be expressed in the vast majority of mouse and human pre-neoplastic skin tumors ([@b4-molce-41-2-73]). The results indicated a strong relationship between cancer stem cells and expression of pluripotency-maintaining transcription factors.

EGCG and green tea extract inhibit the growth of human cancer cell lines in culture and in rodents ([@b16-molce-41-2-73]; [@b37-molce-41-2-73]). Since inhibition of tumor promotion by EGCG is assumed to be strongly related to the non-toxic downregulation of CSCs, we gathered numerous reports from a search of PubMed and published our review article of the literature to provide a broad selection for the effects of EGCG on about 20 human CSCs enriched from cancer cell lines ([@b20-molce-41-2-73]). In the next section, the expression of stemness markers in colorectal and nasopharyngeal CSCs will be introduced as examples, followed by the decrease or increase in stemness markers of human breast, lung and colorectal CSCs by EGCG.

HUMAN CSCS EXPRESS STEMNESS MARKERS DIFFERENTLY FROM THEIR PARENTAL CELLS
=========================================================================

Human CSCs enriched from primary and secondary spheroids are capable of undergoing self-renewal. The quantitative differences in the levels of stemness markers between CSCs and parental cells were studied. The spheroid-derived CSCs, designated HCT116-SDCSCs, exhibit approximately 4.5-fold and 3.2-fold higher expression of stem cell markers, octamer-binding transcription factor 4 (*Oct4*) and Nanog homeobox protein (*Nanog*), respectively, than the parental cells ([@b56-molce-41-2-73]). Oct4, Nanog, and Sox2 are transcription factors required for the maintenance of pluripotency by coordinated networks of transcription factors ([@b4-molce-41-2-73]; [@b28-molce-41-2-73]; [@b39-molce-41-2-73]). Moreover, the expression levels of the surface marker CD44 and self-renewal markers Notch homolog (Notch), B-lymphoma Moloney murine leukemia virus integration site 1 homologue (Bmi-1), CD133, and aldehyde dehydrogenase 1 (ALDH1) are higher in HCT116-SDCSCs than in parental cells ([Table 8](#t8-molce-41-2-73){ref-type="table"}).

Compared with parental cells, human nasopharyngeal sphere-derived cells CSCs, designated TW01, express relatively high levels of the stem cell markers Sox2, Oct4, and Krüppel-like factor (Klf4)*,* plus epithelial-mesenchymal transition (EMT) markers including Twist family BHLH transcription factor (Twist)*,* Snail family transcriptional repressor (Snail), and vimentin*,* along with N-cadherin. However, decreased expression of *E-cadherin* in TW01 sphere-derived cells was detected ([Table 8](#t8-molce-41-2-73){ref-type="table"}) ([@b30-molce-41-2-73]).

EGCG DECREASES THE EXPRESSION OF MRNAS AND PROTEINS THAT SERVE AS STEMNESS MARKERS OF HUMAN CSCS
================================================================================================

Breast CSCs
-----------

EGCG (40 μg/ml, 87.3 μM) inhibits the expression of genes that promote growth and contribute to the transformed phenotype and survival of SUM-190 spheres: In SUM-149 and SUM-190 cells, EGCG decreases the levels of mRNAs of the proliferation markers cyclin D1 (*CCND1)*; ras homolog family member C (*RHOC*); and B-cell lymphoma-extra large (*BCL-XL*), which is a major antiapoptotic protein of the B-cell lymphoma 2 (Bcl2) family. EGCG also decreases ATP levels. In contrast, the levels of *Fibronectin 1* (*FN1*), *E-cadherin* (*CDHI*), and *Vimentin* decreased only in SUM-149 cells ([Table 9](#t9-molce-41-2-73){ref-type="table"}). These results indicate that tumorsphere formation was inhibited by EGCG ([@b31-molce-41-2-73]).

The phenotypes of human estrogen receptor (ER)-negative MDA-MB-231 and MDA-MB-436 cells reflect tumors with a poor prognosis. In ER-negative breast cancer cell lines, ER-α36 is overexpressed and is associated with malignant growth ([@b64-molce-41-2-73]). EGCG (10 -- 40 μM) inhibits tumorsphere formation and down-regulates ER-α36 expression at 24 h, which is consistent with down-regulation of the epidermal growth factor receptor (EGFR). EGCG inhibits the growth of ER-negative human breast CSCs through down-regulation of ER-α36 expression, indicating that EGCG treatment will result in longer survival of patients with mammary cancers ([@b38-molce-41-2-73]). The longer survival of patients who drink green tea was reported by Nakachi's group, as noted in the Introduction ([@b33-molce-41-2-73]).

Lung CSCs
---------

EGCG (0 -- 100 μM) reduces the mRNA and protein levels of the lung CSC markers *CD133*, *CD44*, *ALDH1A1*, *Nanog,* and *Oct4* in CSC-A549 and CSC-H1299 cells, and also the protein levels of markers proliferating cell nuclear antigen (PCNA) and Cyclin D1 as well as that of Bcl2. In addition, EGCG reduces the protein levels of β-Catenin and v-Myc avian myelocytomatosis viral oncogene homolog (c-Myc). However, EGCG increases the levels of Bcl-2-associated X protein (Bax), Caspase 8, and cleaved Caspases-3 and -9 ([Table 9](#t9-molce-41-2-73){ref-type="table"}). These results show that EGCG inhibits proliferation and induces apoptosis of lung CSCs ([@b65-molce-41-2-73]).

Colorectal CSCs
---------------

Compared with parental cells, 5-fluorouracil (5FU)-resistant (5FUR) CRC cells exhibit an increased ability to form spheroids, indicating the presence of a larger CSC population. EGCG (50EμM) inhibits tumorspheroid formation and the expression of the mRNAs of the stem cell markers *Oct4* and *Nanog*. Treatment of 5FUR CRCs with EGCG inhibits expression of all of the following: self-renewal markers that are components of the Notch homolog 1 (Notch) signaling pathway - Notch1, cleaved Notch1, and c-Myc - as well as that of the polycomb repressive complex subunits, Bmi-1, polycomb protein SUZ (Suz12), and enhancer of zeste homologue (Ezh2) ([Table 9](#t9-molce-41-2-73){ref-type="table"}) ([@b56-molce-41-2-73]).

The 30-year history of our studies is summarized in [Fig. 1](#f1-molce-41-2-73){ref-type="fig"}: Primary cancer prevention with green tea is for the general population, and it results in delayed cancer onset and reduced cancer incidence; secondary cancer prevention means early cancer diagnosis and treatment for the general population as well as cancer patients at clinics; and tertiary cancer prevention with the combination of green tea catechin and anticancer compounds is for cancer patients following cancer treatment ([@b16-molce-41-2-73]; [@b18-molce-41-2-73]; [@b19-molce-41-2-73]; [@b20-molce-41-2-73]).
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###### 

Daily green tea consumption and average age at cancer onset[\*](#tfn1-molce-41-2-73){ref-type="table-fn"}

  Gender         Daily consumption of green tea (cups)                              
  -------------- --------------------------------------------- -------------------- --------------------------------------------------------------------
                 Average age at cancer onset (% of patients)                        
  Female (175)   67.0 ± 1.7 (28.0%)                            66.4 ± 1.3 (58.3%)   74.3 ± 2.2 (13.7%)[\*\*](#tfn2-molce-41-2-73){ref-type="table-fn"}
  Male (244)     65.0 ± 1.5 (24.2%)                            67.2 ± 1.0 (46.7%)   68.2 ± 1.1 (29.1%)

All different types of cancer are included,

*P* \< 0.01

###### 

Recurrence rate of breast cancer in relation to daily consumption of green tea

                                   Daily green tea consumption   
  -------------------------------- ----------------------------- ----------------------------------------------------
  Stages I and II (390 patients)                                 
   Recurrence rate (%)             24.3                          16.7[\*](#tfn3-molce-41-2-73){ref-type="table-fn"}
   Disease-free period (years)     2.8                           3.6
  Stage III (82 patients)                                        
   Recurrence rate (%)             48.8                          58.5
   Disease-free period (years)     1.9                           1.9

*P* \< 0.05 in terms of the Cox proportional hazards model.

###### 

Phase II prevention trial of colorectal adenoma recurrence of patients drinking a combination of daily green tea beverage and tablets of G.T.E

  Study in Japan                                                           
  ----------------- ------------------------------------------------------ -----------------------------------------------------------
  Control (20/65)   31.0                                                   4.0 ± 1.3
  G.T.E (9/60)      15.0[\*](#tfn4-molce-41-2-73){ref-type="table-fn"}     3.0 ± 1.0[\*\*](#tfn5-molce-41-2-73){ref-type="table-fn"}
                                                                           
  Study in Korea                                                           
                                                                           
  Groups (cases)    Recurrence rate %                                      Size of the largest polyps (mm)
                                                                           
  Control (43/71)   60.6                                                   4.8 ± 2.4
  G.T.E (20/72)     27.8[\*\*](#tfn5-molce-41-2-73){ref-type="table-fn"}   4.8 ± 2.3

*P* \< 0.05

*P* \< 0.001

###### 

Inhibition of lung metastasis of B16 melanoma cells with peroral administration of EGCG

               Hematogenous metastasis with B16-F10 cells            Lymphogenous metastasis with B16-BL6 cells                                                      
  ------------ ----------------------------------------------------- -------------------------------------------- -------------------------------------------------- -----
  Control      \>150[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}                                                25[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}   
  0.05% EGCG   107[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}     \>29%                                        7[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}    72%
  0.1% EGCG    76[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}      \>50%                                        10[\*](#tfn6-molce-41-2-73){ref-type="table-fn"}   60%

*P* \< 0.01

###### 

Average values of Young's moduli and inhibition of cell motility for B16-F10 mouse melanoma cells

                         EGCG (μM)                                                                                                                             
  ---------------------- ------------- ----------------------------------------------------------- ----------------------------------------------------------- -----------------------------------------------------------
  Young's moduli (kPa)   0.44 ± 0.01   0.58 ± 0.03[\*](#tfn7-molce-41-2-73){ref-type="table-fn"}   0.68 ± 0.03[\*](#tfn7-molce-41-2-73){ref-type="table-fn"}   0.80 ± 0.02[\*](#tfn7-molce-41-2-73){ref-type="table-fn"}
  Cell motility (%)      100           57.1                                                        30.3[\*](#tfn7-molce-41-2-73){ref-type="table-fn"}          12.6[\*\*](#tfn8-molce-41-2-73){ref-type="table-fn"}

*P* \< 0.001

*P* \< 0.0001

###### 

Increase of average values of Young's moduli for human lung cancer cell lines by treatment with EGCG

                EGCG (μM)                                                                 
  ------------- ------------- ----------------------------------------------------------- -----------------------------------------------------------
  H1299 (kPa)   1.24 ± 0.05   2.30 ± 0.07[\*](#tfn9-molce-41-2-73){ref-type="table-fn"}   2.25 ± 0.11[\*](#tfn9-molce-41-2-73){ref-type="table-fn"}
  Lu99 (kPa)    1.29 ± 0.11   1.63 ± 0.08[\*](#tfn9-molce-41-2-73){ref-type="table-fn"}   2.28 ± 0.09[\*](#tfn9-molce-41-2-73){ref-type="table-fn"}

*P* \< 0.0001

###### 

Reduction of tumor volume in xenograft mouse models implanted using human cancer cell lines after treatment with the combination of EGCG and anticancer drugs

                                                                  Tumor volume (% of control)                                                                      
  -------------------------------------------------- ------------ ----------------------------- ---------------------------------------------------- ------ ------ ----------------------
  Prostate cancer cell lines                                                                                                                                       
   PC-3ML                                            Paclitaxel   100                           40.9[a](#tfn10-molce-41-2-73){ref-type="table-fn"}   44.3   0      [@b44-molce-41-2-73]
                                                     Docetaxel    100                           54.1[a](#tfn10-molce-41-2-73){ref-type="table-fn"}   42.4   0      [@b44-molce-41-2-73]
                                                                                                                                                                   
  Average reduction of tumor volume (% of control)                100                           73.5[a](#tfn10-molce-41-2-73){ref-type="table-fn"}   66.3   29.7   [@b18-molce-41-2-73]

228 mg/kg EGCG

###### 

Human CSCs express stemness markers differentially

  Cancers types and names of CSCs               Markers of increased expression                             Markers of decreased expression   References
  --------------------------------- ----------- ----------------------------------------------------------- --------------------------------- ----------------------
  **Colorectal cancer**                                                                                                                       
   HCT116-SDCSCs                    mRNAs:      *Oct4*, *Nanog*,                                                                              [@b56-molce-41-2-73]
                                    Proteins:   CD44, Notch, Bmi-1, CD133, ALDH1                                                              
                                                                                                                                              
  **Nasopharyngeal cancer**                                                                                                                   
   TW01 sphere                      mRNAs:      *Sox2, Oct4, KLf-4*, *Twist, Snail, Vimentin, N-cadherin*   *E-cadherin*                      [@b30-molce-41-2-73]

###### 

EGCG decreases or increases the expression of stemness marker mRNAs and proteins in human CSCs.

  Cancer types and names of CSCs   Inhibited expression of stemness markers (mRNAs and proteins)   References                                                                  
  -------------------------------- --------------------------------------------------------------- --------------------------------------------------------------------------- ----------------------
  **Breast CSCs**                                                                                                                                                              
   SUM-149 & SUM-190               mRNAs:                                                          *CCND1, RHOC, BCL-XL*                                                       [@b31-molce-41-2-73]
   SUM-149                         mRNAs:                                                          *FN1, CDHI, Vimentin*                                                       
                                                                                                                                                                               
  **Lung CSCs**                                                                                                                                                                
   A549 & H1299                    mRNAs:                                                          *CD133, CD44, ALDH1A1, Nanog, Oct4*                                         [@b65-molce-41-2-73]
                                   Proteins:                                                       CD133, CD44, ALDH1A1, Nanog, Oct4, PCNA, CyclinD1, Bcl2, β-Catenin, c-Myc   
                                   Increased                                                       Bax, Caspase8, Cleaved Caspase-3 and -9                                     
                                                                                                                                                                               
  **Colorectal CSCs**                                                                                                                                                          
   HCT116-5FUR & SW480-5FUR        mRNAs:                                                          *Oct4, Nanog*                                                               [@b56-molce-41-2-73]
  Proteins:                        Notch 1, cleaved-Notch 1, c-Myc, Bmi-1, Suz12, Ezh2                                                                                         
